

# 39<sup>th</sup> International Conference on Screening for Lung Cancer & 8<sup>th</sup> Conference on Research for Early Lung Cancer Treatment



October 16<sup>th</sup> & 17<sup>th</sup>, 2018  
Hosted by: Vassar Brothers Medical Center  
Hyde Park, NY, 12538

The mission of our conference is to understand the issues surrounding early diagnosis of lung cancer, how to optimize early treatment, and to expand practice-relevant research to medical and scientific communities in the U.S. and abroad. The Early Lung Cancer Action Program (ELCAP) screening effort began in 1992 and evolved into the International Early Lung Cancer Action Program (I-ELCAP). By providing training and the ELCAP Management System to those interested in screening, these programs expanded worldwide. The resulting data and analyses provide new diagnostic knowledge that is being continually integrated into the screening regimen so that it remains state-of-the-art. The screening advances are addressed at every conference. In addition, the Early Lung Cancer Research on Treatment (IELCART) uses the power of the prospective cohort design to accumulate data on treatment delivered for Stage I lung cancer and to address questions about optimal treatment. The IELCART research goal is to maximize the benefit of screening by determining optimal treatment for these Stage I lung cancer patients. Finally, the newest focus of research at this conference is interstitial lung disease (ILD) as this disease often affects older smokers. Following the same research paradigms as I-ELCAP & IELCART, an ILD registry has been developed and collaborating sites have been recruited.

## Tuesday, October 16<sup>th</sup>

**9:00 – 9:30**

**Welcome.**

**Conference Welcome.** *J. P. Smith, I-ELCAP Advisory Board*

**Program Overview.** *C. Henschke*

**I-ELCAP and IELCART Update.** *C. Henschke*

**9:30 – 11:00**

**Global Updates of Screening Initiatives.** Moderator: *C. Connery*

9:30 – 9:45

A High Risk Lung Cancer Screening Program: The Canadian Way. *H. Schmidt*

9:45 – 10:00

Initiatives in China. *W. Tang*

10:00 – 10:15

Poland and Eastern Europe. *W. Rzyman*

10:15 – 10:30

European Position Statement and Implementation. *J. Field*

10:30 – 10:45

Screening in Brazil. *R. Sales dos Santos*

10:45 – 11:00

IASLC Lung Cancer Screening Initiative. *J. Mulshine*

**11:00 – 11:15**

**COFFEE BREAK**

**11:15– 12:30**

**Stage I Lung Cancer.** Moderator: *F. Grannis*

11:15 – 11:30

Surgical morbidity and mortality for Stage I lung cancer in CALGB. *N. Altorki*

11:30 – 11:45

Surgical morbidity and mortality in Stage I lung cancer in IELCART. *D. Nicastrì*

11:45 – 12:00

Radiotherapy for Stage I. *K. Rosenzweig*

12:00 – 12:15

Sentinel lymph nodes in Stage I. *M. Quereshi*

12:15 – 12:30

Tumor microenvironment and prognoses. *H. Pass*

**12:30 – 1:30**

**LUNCH**

**1:30 – 2:30**

**Preliminary findings from IELCART.** Moderator: *H. Pass*

1:30 – 1:45

Why the robot? *C. Connery*

1:45 – 2:00

Why not? *R. Flores*

2:00 – 2:15

What drives decisions in IELCART. *R. Yip*

2:15 – 2:30

Role of FNA in IELCART. *D. Yankelevitz*

## Tuesday, October 16<sup>th</sup> (continued)

- 2:30 – 3:30**      **Aggressiveness of Stage I Lung Cancer** Moderator: D. Yankelevitz  
2:30 – 2:45      Size, grade, histology what do we know? *E. Burks*  
2:45 – 3:00      Neoadjuvant therapy in early stage NSCLC. *F. Hirsch*  
3:00 – 3:15      Tumor doubling times, PET scans and prognosis. *Y. Wang*  
3:15 – 3:30      Molecular characterization and prognosis. *L. Montuenga*
- 3:30 – 4:00**      **COFFEE BREAK**
- 4:00 – 4:45**      **Panel Discussion of Difficult Cases.** Moderator: *T. Collins*  
Panel members: *H. Suseelan, M. Salvatore, L. DiFabrizio, R. Flores, C. Connery*
- 4:45 – 5:45**      **Closed Meeting for I-ELCAP and IELCART Members**
- 7:00 – 9:00**      **CONFERENCE DINNER – Culinary Institute of America**

## Wednesday, October 17<sup>th</sup>

- 9:00 – 10:15**      **Screening updates.** Moderator: *J. Mulshine*  
9:00 – 9:15      Quantitative Screening Report. *A. Reeves*  
9:15 – 9:30      Why are we not performing more screening? *A. McKee*  
9:30 – 9:45      Nodule growth? *D. Yankelevitz*  
9:45 – 10:00      Low-dose radiation. *R. Subramaniam*  
10:00 – 10:15      Efficiency of ACR-LungRADS and I-ELCAP. *C. Henschke*
- 10:15 – 10:45**      **COFFEE BREAK**
- 10:45 – 11:30**      **New Horizons.** Moderator: *J. Mulshine*  
10:45 – 11:00      Where will improved image quality take us. *R. Avila*  
11:00 – 11:15      Lessons learned from social media. *V. Krishnamurthy*  
11:15 – 11:30      Using AI for outreach to smokers. *A. Ramos*
- 11:30 – 12:30**      **Heart Disease and CT screening.** Moderator: *K. Haleem*  
11:30 – 11:45      Does heart size matter and how to measure it? *J. Ling*  
11:45 – 12:00      Coronary artery disease in high-performance athletes. *K. Haleem*  
12:00 – 12:15      Coronary contrast CT approaches. *M. Yen*  
12:15 – 12:30      Aortic aneurysms and monitoring. *A. Messina*
- 12:30 – 1:15**      **LUNCH**
- 1:15 – 2:15**      **Health Check.** Moderator: *D. Yankelevitz*  
1:15 – 1:30      Why the distinction between cancer screening and health check? *L. Fenton*  
1:30 – 1:45      Title TBD. *A. McGlothlin*  
1:45 – 2:00      Implications of aortic valve calcifications. *Y. Zhu*  
2:00 – 2:15      Reporting ancillary findings and legal considerations. *L. Goldsmith*
- 2:15 – 3:15**      **Update on VA-PALS.** Moderator: *C. Henschke*  
2:15 – 2:30      Update on VA-PALS and VALOR. *D. Moghanaki*  
2:30 – 2:45      Implementation at the Phoenix VA. *S. Aguayo*  
2:45 – 3:00      Development of VA QA for screening. *D. Yankelevitz*  
3:00 – 3:15      Implementation Assessment. *J. Lewis, L Spalluto*
- 3:15 – 4:00**      **Interstitial Lung Disease.** Moderator: *T. Collins*  
3:15 – 3:30      ILD in the community setting. *H. Suseelan*  
3:30 – 3:45      Meta-analysis of ILD and lung cancer. *M. Salvatore*  
3:45 – 4:00      Next generation treatments for ILD and monitoring them. *M. Padilla*